Has Kathryn Lucas, MD received payments from drug or device companies?

Yes. Drug and device makers reported $37,936,017 in general payments to Kathryn Lucas, MD across 9,558 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kathryn Lucas, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kathryn Lucas, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kathryn Lucas, MD

Endocrinology, Diabetes & Metabolism · Morehead City, NCNPI 1407892441

Payments from drug & device makers

$37,936,017in general payments, 2019–2025

Across 9,558 payments — averaging $3969.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Modernatx, Inc.$11.7M
Eli Lilly$5M
Novartis$3.7M
Boehringer Ingelheim$3.4M
AbbVie$2.9M
Sanofi US Services Inc.$2.1M
plus $9.1M from 38 others

$283,754in research payments, 2019–2025

Across 27 payments — averaging $10,509 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$220K
Valneva Austria GmbH$62K
AbbVie$2K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Modernatx, Inc.	7,385	$11,671,507
Eli Lilly	136	$5,023,948
Novartis	43	$3,746,629
Boehringer Ingelheim	109	$3,407,280
AbbVie(2 entities)	245	$2,854,229
Sanofi US Services Inc.	665	$2,094,118
Valneva Austria GmbH	14	$1,832,652
Astrazeneca UK Limited	9	$1,688,375
Intercept Pharmaceuticals, Inc.	68	$1,068,406
Roche Diagnostics Operations, Inc.	25	$619,625
Eisai Inc.	20	$583,668
Roche Molecular Systems, Inc.	24	$500,298
Kowa Research Institute, Inc.	52	$398,578
GSK	77	$334,454
Sanofi Pasteur Inc.	10	$327,788
Chugai Pharmaceutical Co., Ltd.	23	$303,742
AstraZeneca	12	$245,830
Akcea Therapeutics, Inc.	4	$186,527
Lexicon Pharmaceuticals, Inc.	10	$185,839
Madrigal Pharmaceuticals	42	$152,363
Amgen	4	$115,352
Gilead	26	$110,445
Merck	7	$106,517
IBSA Institut Biochimique SA	8	$92,800
Boehringer Ingelheim International GmbH	185	$71,132
Esperion Therapeutics, Inc.	79	$50,961
Dexcom, Inc.	15	$32,951
Takeda Pharmaceuticals U.S.A., Inc.	11	$30,897
Sanofi-aventis U.S. LLC	28	$28,555
Boehringer Ingelheim France S.a.s.	147	$24,366
Boehringer Ingelheim RCV GmbH & Co KG	30	$16,271
E.r. Squibb & Sons, L.L.C.	3	$12,095
Boehringer Ingelheim Pharma GmbH & Co.kg	6	$7,845
Novo Nordisk	11	$7,380
Tandem Diabetes Care, Inc.	10	$2,138
United Therapeutics Corporation	1	$123
Lilly USA, LLC	3	$95
Insulet Corporation	2	$68
Mayne Pharma Commercial LLC	4	$65
Boston Scientific	1	$37
Rhythm Pharmaceuticals, Inc.	1	$23
Echosens North America, Inc.	1	$21
Abbott	1	$18
Cequr Corporation	1	$4

How this compares

$37,936,017 in reported general payments places this provider in the 95th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.

See all endocrinology, diabetes & metabolism providers in North Carolina →

Medicare billing

Part B allowed, 2024

$59,358

Medicare patients

221

Services billed

2,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Morehead City

Mary LawrenceMorehead City$4.9M
Mark WarrenGreenville$5M
John ParkerWilmington$4.1M
John BuseChapel Hill$3.8M
Wendy LaneAsheville$1.9M
Anthony BarberHickory$1.4M
Klara KleinChapel Hill$1.3M
Thomas OconnellBurlington$805K
Corey BerlinRaleigh$742K
Michael FavoritoWilmington$723K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →